Previous observations that injecting this naturally derived proinsulin peptide C19-A3 in humans is safe and that tolDC regulate antigen-specific immune responses in vitro prompted us to assess this peptide-cell combination for clinical intervention in T1D patients (6, 18, 19). This evidence concerns the gene INS and type 1 diabetes mellitus.